title: Cabergoline therapy for Cushing disease throughout pregnancy.
abstract: BACKGROUND
  Cushing disease during pregnancy is rare and is associated with significant maternal and fetal morbidity and mortality. Transsphenoidal pituitary surgery is the first-line therapy; however, in cases of failed surgery or in patients who are not surgical candidates, medical therapy has been used to control symptoms.
  
  
  METHODS
  A 29-year-old woman with Cushing disease and a noncurative transsphenoidal pituitary surgery was successfully treated with cabergoline, a dopamine agonist. After approximately 1 year of therapy, she became pregnant. She was maintained on high-dose cabergoline throughout her pregnancy and had an uncomplicated antenatal course. She went into spontaneous labor at 38 weeks of gestation and delivered a healthy female neonate.
  
  
  CONCLUSIONS
  Cabergoline can be used to manage Cushing disease successfully during pregnancy with an opportunity for a favorable outcome.
authors.affiliation: Department of Gynecology and Obstetrics and Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: Irene
authors.initials: I
authors.lastname: Woo
authors.forename: Robert M
authors.initials: RM
authors.lastname: Ehsanipoor
mesh_terms: D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D050498:Live Birth; D047748:Pituitary ACTH Hypersecretion / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline